IP Library Patent Application 12137914
Patent Application
App. No. 12/137,914

METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/137,914
Abstract

The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.

Claims (1)

1 . An isolated double stranded nucleic acid comprising a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein said double stranded nucleic acid comprises a blunt end, wherein each of said first and said second strands consists of the same number of nucleotide residues and is 25-30 nucleotides, wherein the ultimate and penultimate residues of said 3′ terminus of said first strand and the ultimate and penultimate residues of said 5′ terminus of said second strand form one or two mismatched base pairs, and wherein said second oligonucleotide strand is sufficiently complementary to a target RNA along at least 19 nucleotides of said second oligonucleotide strand length to reduce target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 5, 2017
From: JPMORGAN CHASE BANK, N.A.
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 043800/0186 →
SECURITY AGREEMENT Recorded Apr 26, 2010
From: INTEGRATED DNA TECHNOLOGIES, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 024286/0152 →
RELEASE OF SECURITY INTEREST Recorded Apr 23, 2010
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 024278/0374 →
SECURITY AGREEMENT Recorded Jun 18, 2009
From: INTEGRATED DNA TECHNOLOGIES, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 022846/0023 →